|Application ||IHC-P, E|
|Other Accession||AAH71556, 47940064|
|Calculated MW||137412 Da|
|Application Notes||TTBK2 antibody can be used for detection of TTBK2 by immunohistochemistry at 5 µg/mL.|
|Target/Specificity||TTBK2; TTBK2 antibody is human specific. At least four isoforms of TTBK2 are known to exist; this antibody will detect only the two largest isoforms.|
|Reconstitution & Storage||TTBK2 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.|
|Precautions||TTBK2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Serine/threonine kinase that acts as a key regulator of ciliogenesis: controls the initiation of ciliogenesis by binding to the distal end of the basal body and promoting the removal of CCP110, which caps the mother centriole, leading to the recruitment of IFT proteins, which build the ciliary axoneme. Has some substrate preference for proteins that are already phosphorylated on a Tyr residue at the +2 position relative to the phosphorylation site. Able to phosphorylate tau on serines in vitro.|
|Cellular Location||Cell projection, cilium. Cytoplasm, cytoskeleton, cilium basal body Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole. Cytoplasm, cytosol. Nucleus. Note=Localizes to the transition zone in primary cilia in response to cell cycle signals that promote ciliogenesis (By similarity). May also be present in cytosol and, at lower level in the nucleus|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
TTBK2 Antibody: Tau tubulin kinase (TTBK2) is a serine/threonine kinase whose substrates are thought to include the tau and tubulin proteins. Mutations in the TTBK2 gene cause spinocerebellar ataxia type 11 (SCA11), a neurodegenerative disease characterized by progressive ataxia and atrophy of the cerebellum and brainstem. Recent studies have shown that increased levels of TTBK2 expression in kidney carcinoma and melanoma cell lines increases resistance to the chemotherapeutic agent Sunitinib, and that reduction of TTBK2 though the use of siRNA sensitized these cell lines to the effects of Sunitib, suggesting that TTBK2 can be used as a resistance marker as well a potential target to overcome resistance.
Kitano-Takahashi M, Morita H, Kondo S, et al. Expression, purification and crystallization of a human tau-tubulin kinase 2 that phosphorylates tau protein. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 2007; 63:602-4.
Edener U, Kurth I, Meiner A, et al. Missense exchanges in the TTBK2 gene mutated in SCA11. J. Neurol. 2009; 1856-9.
Bender C and Ullrich A. PRKX, TTBK2 and RSK4 expression causes sunitinib resistance in kidney carcinoma- and melanoma cell lines. Int. J. Cancer 2011; epub.
If you have any additional inquiries please email technical services at email@example.com.